Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Xeris Pharmaceuticals Inc.

www.xerispharma.com

Latest From Xeris Pharmaceuticals Inc.

Keeping Track: US FDA Clears Two More Biosimilars, First Non-Injectable Glucagon

The latest drug development news and highlights from our US FDA Performance Tracker.

Approvals Drug Review

Keeping Track: Approvals For Polivy, Keytruda, FDA Applause For Biosimilars

The latest drug development news and highlights from our US FDA Performance Tracker.

Approvals Biosimilars

US FDA Approval Actions To Watch Out For In June

User fee goal date calendar for June includes AMAG’s female sexual dysfunction drug Vyleesi, new indications for Sanofi/Regeneron’s Dupixent in rhinosinusitis and Merck’s Zerbaxa in nosocomial pneumonia.

Drug Review Drug Approval Standards

Finance Watch: Anchiano, TCR2, Hoth And Stealth Make Seven US Biopharma IPOs For 2019

Public Company Edition: Four more IPOs in the US bring the year's total to seven – all in February. Also, Agenus launched its digital security offering, MacroGenics leads recent follow-on offerings and four companies reveal new job cuts.

Financing Business Strategies
See All

Company Information

  • Industry
  • Biotechnology
    • Large Molecule
  • Medical Devices
  • Pharmaceuticals
    • Drug Delivery
      • Macromolecule
  • Therapeutic Areas
  • Metabolic Disorders
  • Alias(es)
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Xeris Pharmaceuticals Inc.
  • Senior Management
  • Paul R Edick, Pres. & CEO
    Barry Deutsch, CFO
    Steven Prestrelski, PhD, CSO
  • Contact Info
  • Xeris Pharmaceuticals Inc.
    Phone: (844) 445-5704
    180 N. LaSalle St., Ste. 1800
    Chicago, IL 60601
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register